Last reviewed · How we verify
Octafluoropropane
Octafluoropropane is a Small molecule drug developed by University of Alabama at Birmingham. It is currently in Phase 1 development for Echocardiography. Also known as: Definity.
Octafluoropropane, also known as perfluoropropane, is a synthetic, non-flammable, and non-toxic substance used in semiconductor production and medicine. It is classified as a small molecule diagnostic agent, used in medical imaging techniques such as MRI.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Octafluoropropane |
|---|---|
| Also known as | Definity |
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Approved indications
- Echocardiography
Common side effects
Key clinical trials
- Influence of Tamponade on Retinal Shift in Eyes Undergoing Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparison of Gas Versus Silicone Oil in a Pakistani Population (NA)
- Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy (EARLY_PHASE1)
- SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial (PHASE2)
- Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease (PHASE2)
- Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma (NA)
- Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer (PHASE2, PHASE3)
- 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
- Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octafluoropropane CI brief — competitive landscape report
- Octafluoropropane updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI
Frequently asked questions about Octafluoropropane
What is Octafluoropropane?
What is Octafluoropropane used for?
Who makes Octafluoropropane?
Is Octafluoropropane also known as anything else?
What development phase is Octafluoropropane in?
Related
- Manufacturer: University of Alabama at Birmingham — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Echocardiography
- Also known as: Definity
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing